Focus on tumor gene detection! KingMed and Illumina have reached a new strategic cooperation

On July 27, Illumina and KingMed Diagnostics Group Co., Ltd. reached a new strategic cooperation on tumor gene detection. The two sides will fully combine their respective advantages, promote the development of NGS technology in the application of precise management of the whole course of cancer, and jointly promote the precise medical detection program to benefit more Chinese patients.

Yaoming Liang, chairman and CEO of KingMed, said: "As a leader in the third-party medical examination industry, KingMed has a comprehensive technical platform, a nationwide service network and strong operational capabilities, and is committed to providing high-quality, affordable and accessible medical examination services for clinical and patients. In the future, KingMed will work with Illumina to give full play to their respective advantages and provide patients with higher quality, cost-effective and standardized tumor gene testing."

Li Qing, senior vice president and general manager of Greater China, said: "Since entering the Chinese market, Illumina has always adhered to the localization strategy of 'in China, for China' and worked with Chinese partners to create a localized precision medicine innovative testing program that meets the needs of Chinese patients. KingMed is a leading enterprise in China's medical testing industry, and we are happy to push the cooperation between the two sides to a new stage. I believe that with the joint efforts of both sides, more Chinese cancer patients will be able to obtain high quality." Quantity of precision medical testing products. "